Samsung Biologics Acquires GSK's Human Genome Sciences, Expanding U.S. Manufacturing Capacity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Newsfilter
- Strategic Acquisition: Samsung Biologics secures its first U.S. manufacturing site by acquiring GSK's Rockville facility for $280 million, enhancing the diversity and resilience of its global supply chain.
- Capacity Expansion: The site, with a capacity of 60,000 liters for drug substance, will see further investments to expand its capabilities, supporting growing manufacturing programs and ensuring a stable supply of critical biologic medicines.
- Employee Retention: Over 500 employees will be retained post-acquisition to ensure operational continuity and stability, providing reliable life-saving therapeutics to American patients.
- Market Commitment: This acquisition underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry, expected to deepen collaboration with federal and local stakeholders to advance global healthcare initiatives.
GSK
$48.61+Infinity%1D
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 48.290
Low
45.00
Averages
45.00
High
45.00
Current: 48.290
Low
45.00
Averages
45.00
High
45.00
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
